Kura Oncology Reports Third Quarter 2016 Financial Results
November 07, 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference
November 04, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the company’s...
Kura Oncology to Participate in Two Upcoming Investor Conferences
November 01, 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and...
Kura Oncology to Report Third Quarter 2016 Financial Results
October 31, 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the 2016 Aegis Growth Conference
September 14, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth...
Kura Oncology Reports Second Quarter 2016 Financial Results
August 10, 2016 16:03 ET
|
Kura Oncology, Inc.
Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host webcast and conference call today at...
Kura Oncology to Report Second Quarter 2016 Financial Results
August 03, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial...
Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
January 14, 2016 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in...
TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
November 02, 2015 07:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase...
TetraLogic Announces Update on MDS Clinical Program
June 30, 2015 16:01 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., June 30, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...